CD36 and melanoma: In silico prediction indicated a potential role of PRKC – in line with complementary observations by others: PRKC phosphorylates CD36 and thereby blocks binding of Thrombospondin‐1 in melanoma cells.52 It changes phosphorylation patterns of CD44 that result in alterations of cell motility.53 Regarding ITGA6, PRKC is necessary for the chemotactic migration of (squamous) carcinoma cells via its ability to mobilize ITGA6B4 from hemidesmosomes.54